INDV Q3 2024 Earnings — Indivior Pharmaceuticals Inc Revenue & Financial Results | Market Cap Arena

INDVIndivior Pharmaceuticals Inc

$4B

Q3 2024 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$307M+13.3% YoY

Gross Profit

$238M77.5% margin

Operating Income

$4M1.3% margin

Net Income

$4M1.3% margin

EPS (Diluted)

$0.03

QoQ Revenue Growth

+2.7%

Cash Flow

Operating Cash Flow

$8M

Free Cash Flow

-$1M

Stock-Based Comp.

$7M

Balance Sheet

Total Assets

$1.5B

Total Liabilities

$1.6B

Stockholders' Equity

-$167M

Cash & Equivalents

$288M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$307M	$271M	+13.3%
Gross Profit	$238M	$225M	+5.8%
Operating Income	$4M	-$183M	+102.2%
Net Income	$4M	-$135M	+103.0%